Multicomponent Vaccine For COVID-19, Influenza Shows Promise, Study Finds

Infectious Disease Advisor (7/3, Basilio) reported a study found that “the investigational multicomponent mRNA-1083 vaccine is noninferior to coadministered seasonal influenza and COVID-19 vaccines, eliciting higher immune responses against 3 influenza strains and an acceptable safety profile in adults.” Overall, researchers observed that “the multicomponent mRNA-1083 vaccine demonstrated noninferiority vs active comparators against all vaccine-matched influenza and SARS-CoV-2 strains based on prespecified success criteria. Moreover, patients with and without high-risk comorbid conditions who received mRNA-1083 showed comparable immune responses.” They noted that among younger participants, “mRNA-1083 was superior to coadministered SD-IIV4 plus mRNA-1273 for protection against 4 influenza strains (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) and SARS-CoV-2 (XBB.1.5).” The study was published in JAMA.